In summary, emavusertib (CA4948) monotherapy appeared to be most effective in primary AML with FLT3 and NPM1 gene mutations and the absence of gene mutations in TP53 and epigenetic modifiers, as well as moderate CD34 positivity. Here, FLT3 is linked to acute myeloid leukemia.